Exscientia Links With Scripp Research’s Calibr To Apply AI To COVID-19
UK Diamond Light Source And Oxford University Part Of Initiative
Executive Summary
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.
You may also be interested in...
AbbVie To Build On Relationship With Calibr Via Five-Year Extension
Deal Snapshot: Previously partnered on CAR-T therapies for cancer and COVID-19 antivirals, AbbVie and Scripps’ discovery unit Calibr unveil a five-year extension, including new targets and preclinical candidates.
Dainippon Lays Out R&D Table Ahead Of Latuda Challenges
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.